丁酸叔丁酯 | 2308-38-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 丁酸叔丁酯
• 英文名称: tert-butyl butyrate
• 英文别名: tert-butyl butanoate；Butanoic acid, 1,1-dimethylethyl ester
• CAS: 2308-38-5
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: TWBUVVYSQBFVGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  -88.07°C (estimate)
• 沸点：
  136.25°C
• 密度：
  0.8836 (estimate)
• 保留指数：
  851;858;866;873;873;862

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  丁酸叔丁酯 生成 2-硝基丁酸乙酯
  参考文献：
  名称：

  Alkyl nitrate nitration of active methylene compounds. VI. Nitration of esters in liquid ammonia

  摘要：

  DOI：

  10.1021/jo01256a048
• 作为产物：
  描述：

  2-bromo-1,1-dimethylethyl butanoate 在 三正丁基氢锡 作用下， 以 various solvent(s) 为溶剂， 反应 1.0h， 生成 丁酸叔丁酯
  参考文献：
  名称：

  Beckwith, Athelstan L. J.; Duggan, Peter J., Journal of the Chemical Society. Perkin transactions II, 1992, # 10, p. 1777 - 1783

  摘要：

  DOI：

文献信息

• Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20170291911A1

  公开（公告）日：2017-10-12

  The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.

  该披露涉及抑制共济失调毛细血管扩张性和Rad3相关蛋白激酶（ATR）的化合物和组合物，以及它们的使用方法。
• SOLUBLE GUANYLATE CYCLASE STIMULATORS
  申请人：Berger Raphaelle

  公开号：US20170174693A1

  公开（公告）日：2017-06-22

  The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R 1 , R 2 , R 4 , R a , and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

  该发明提供了Formula (I)的化合物或其药用盐，其中X、Y、Z、R1、R2、R4、Ra以及下标m、p和q如本文所述。这些化合物或其药用盐可以调节人体对环鸟苷酸单磷酸（“cGMP”）的产生，并通常适用于治疗和预防与扰乱的cGMP平衡相关的疾病。该发明还提供了包含Formula (I)的化合物或其药用盐的药物组合物。该发明还涉及使用这些化合物或其药用盐在治疗和预防上述疾病以及为此目的制备药物的方法。
• Copper-catalyzed oxidative esterification of aldehydes with dialkyl peroxides: efficient synthesis of esters of tertiary alcohols
  作者：Yefeng Zhu、Yunyang Wei

  DOI：10.1039/c3ra40246k

  日期：——

  Copper-catalyzed oxidative esterification of aldehydes with dialkyl peroxides has been developed. This protocol affords a novel approach for the synthesis of carboxylic esters of tertiary alcohols under mild conditions. Depending on the catalyst system, a variety of tertiary esters were produced in good to excellent yields.

  已经开发了铜催化的醛与二烷基过氧化物的氧化酯化反应。该方案提供了一种在温和条件下合成叔醇羧酸酯的新方法。根据催化剂体系的不同，可以产生高至优收率的各种叔酯。
• [EN] PI-3 KINASE INHIBITOR PRODRUGS<br/>[FR] PROMEDICAMENTS D'INHIBITEURS DE PI-3 KINASE
  申请人：SEMAFORE PHARMACEUTICALS INC

  公开号：WO2004089925A1

  公开（公告）日：2004-10-21

  The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

  这项发明提供了PI-3激酶抑制剂的新型前药。这些新型化合物是LY294002及其类似物，包括可逆性季铵化胺。
• Substituted arylpyrazoles
  申请人：Billen Denis

  公开号：US20060287365A1

  公开（公告）日：2006-12-21

  This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.

  这项发明涉及一系列1-芳基-4-环丙基吡唑，其中环丙基环在角位被取代，以及其药用盐和溶剂合物，包括这些化合物的组合物，它们的合成过程以及它们作为驱虫剂的用途。

表征谱图